A phase 1, multicenter, open-label, dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and clinical activity of orally administered LP-108 (lacutoclax) as monotherapy and in combination with azacitidine in subjects with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Burgues, J. M. B.; Koenig, K.; Montesinos, P.; Bixby, D. L.; Burke, P. W.; Daver, N.; Anthony, S. P.; Tan, F. L.; Chen, Y.; Chen, Y.; Aviles, I. C.; Curran, E. K. |
| Abstract Title: | A phase 1, multicenter, open-label, dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and clinical activity of orally administered LP-108 (lacutoclax) as monotherapy and in combination with azacitidine in subjects with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 6009 |
| End Page: | 6010 |
| Language: | English |
| ACCESSION: | WOS:001412527900008 |
| DOI: | 10.1182/blood-2024-208792 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
